Display options
Cite
Sutton SS, Jumper M, Cook S, et al. Ertapenem-Induced Encephalopathy in a Patient With Normal Renal Function. J Investig Med High Impact Case Rep. 2017;5(1):2324709616689376doi: 10.1177/2324709616689376.
Sutton, S. S., Jumper, M., Cook, S., Edun, B., & Wyatt, M. D. (2017). Ertapenem-Induced Encephalopathy in a Patient With Normal Renal Function. Journal of investigative medicine high impact case reports, 5(1), 2324709616689376. https://doi.org/10.1177/2324709616689376
Sutton, S Scott, et al. "Ertapenem-Induced Encephalopathy in a Patient With Normal Renal Function." Journal of investigative medicine high impact case reports vol. 5,1 (2017): 2324709616689376. doi: https://doi.org/10.1177/2324709616689376
Sutton SS, Jumper M, Cook S, Edun B, Wyatt MD. Ertapenem-Induced Encephalopathy in a Patient With Normal Renal Function. J Investig Med High Impact Case Rep. 2017 Jan 01;5(1):2324709616689376. doi: 10.1177/2324709616689376. eCollection 2017. PMID: 28203577; PMCID: PMC5298517.
Copy Download .nbib Format: NLM
Share it on

J Investig Med High Impact Case Rep. 2017 Jan 01;5(1):2324709616689376. doi: 10.1177/2324709616689376. eCollection 2017.

Ertapenem-Induced Encephalopathy in a Patient With Normal Renal Function.

Journal of investigative medicine high impact case reports

S Scott Sutton, Mark Jumper, Sean Cook, Babatunde Edun, Michael D Wyatt

Affiliations

  1. University of South Carolina, Columbia, SC, USA.
  2. Dorn Veterans Affairs Medical Center, Columbia, SC, USA.

PMID: 28203577 PMCID: PMC5298517 DOI: 10.1177/2324709616689376

Abstract

Drug-induced neurotoxicity is a rare adverse reaction associated with ertapenem. Encephalopathy is a type of neurotoxicity that is defined as a diffuse disease of the brain that alters brain function or structure. We report a patient with

Keywords: drug-induced encephalopathy; drug-induced neurotoxicity; ertapenem

Conflict of interest statement

Declaration of Conflicting Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

References

  1. Intern Med J. 2014 Aug;44(8):817-9 - PubMed
  2. J Antimicrob Chemother. 2000 Jan;45(1):5-7 - PubMed
  3. Pharmacotherapy. 2011 Apr;31(4):408-23 - PubMed
  4. Am J Med. 1988 May;84(5):911-8 - PubMed
  5. Clin Nephrol. 2013 Dec;80(6):474-8 - PubMed
  6. J Antimicrob Chemother. 1991 Apr;27(4):405-25 - PubMed
  7. J Antibiot (Tokyo). 1995 May;48(5):408-16 - PubMed
  8. Ann Pharmacother. 2011 Jan;45(1):e6 - PubMed
  9. Antimicrob Agents Chemother. 1993 Feb;37(2):199-202 - PubMed
  10. J Clin Pharm Ther. 2015 Apr;40(2):240-4 - PubMed
  11. Crit Care Clin. 1997 Oct;13(4):741-62 - PubMed
  12. N Z Med J. 2009 Jul 03;122(1298):76-7 - PubMed
  13. Eur J Clin Microbiol Infect Dis. 2005 Oct;24(10):649-53 - PubMed
  14. Int J Antimicrob Agents. 2004 Mar;23(3):213-7 - PubMed
  15. Clin Pharmacol Ther. 1981 Aug;30(2):239-45 - PubMed
  16. J Antimicrob Chemother. 2014 Aug;69(8):2043-55 - PubMed
  17. Drug Saf. 1996 Aug;15(2):87-90 - PubMed
  18. Int J Clin Pharm. 2013 Aug;35(4):535-7 - PubMed
  19. Drug Saf. 2000 Mar;22(3):191-4 - PubMed
  20. Toxicology. 2006 May 1;222(1-2):114-24 - PubMed
  21. Br J Clin Pharmacol. 2011 Sep;72(3):381-93 - PubMed
  22. Pediatr Infect Dis J. 1991 Feb;10(2):122-5 - PubMed
  23. Am J Med. 1985 Jun 7;78(6A):73-8 - PubMed
  24. Arch Intern Med. 1987 Aug;147(8):1430-3 - PubMed

Publication Types